Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Entecavir Is 1st-Choice Drug for Chronic Hepatitis B: Dr Kumada
April 2, 2007
- Korosho Orders Chugai to Issue "Dear-Doctor Letter" on Tamiflu
April 2, 2007
- NEW PRODUCTS
April 2, 2007
- Relenza in Short Supply
April 2, 2007
- Eli Lilly to Enhance Presence in GP Market: Mr Crenshaw
April 2, 2007
- Council to Propose Strategies to Enhance Global Competitiveness
April 2, 2007
- Eisai Embarks on Antibody Pharmaceuticals Business by Acquiring Morphotek
April 2, 2007
- Korosho Proposes 7 Measures to Promote Innovation
March 26, 2007
- Japan-China Medical Cooperation Initiatives to Symbolize Fraternity: Mr Niwa
March 26, 2007
- R&D NEWS IN BRIEF
March 26, 2007
- FPMAJ to Propose NHI Pricing System Reform Plan in August
March 26, 2007
- Results of J-LIT Subanalysis Published: Banyu
March 26, 2007
- Required Nos. of Japanese Subjects Are Not Exorbitant: Mr Mori from PMDA
March 26, 2007
- Philips Simplicity Event in Hong Kong Highlights Philips' "Sense and Simplicity" in Healthcare
March 26, 2007
- REGULATORY NEWS IN BRIEF
March 26, 2007
- Takeda Acquires Paradigm of the UK
March 26, 2007
- Operating Profit Rate for 28 FJPWA-Affiliated OTC Drug Wholesalers Up 0.41 Points
March 26, 2007
- Nippon Chemiphar to Enter Chinese Market, Expand Generic Business
March 26, 2007
- Spread of Use of Steroids Reduces Asthma Deaths: GSK Seminar
March 26, 2007
- SymBio Licenses AB-1001 from Abeille
March 26, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…